- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01128543
Lapatinib in Combination With Vinorelbine
A Multicenter, Open-Label, Phase II Study of Lapatinib in Combination With Vinorelbine in Subjects With ErbB2 Amplified Recurrent and Metastatic Breast Cancer
Study Overview
Detailed Description
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior chemotherapy or anti-HER2/neu targeted therapy in the metastatic and relaps setting.
Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks. The study treatment will continue until patients experience disease progression or unacceptable toxicity. The primary objective of the study is the objective response rate (ORR, defined as CR + PR) and toxicity. Secondary objectives include DFS, duration of response.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ankara, Turkey, 06100
- GSK Investigational Site
-
Ankara, Turkey, 06500
- GSK Investigational Site
-
Ankara, Turkey, 06590
- GSK Investigational Site
-
Diskapi / Ankara, Turkey, 337088
- GSK Investigational Site
-
Diyarbakir, Turkey, 21280
- GSK Investigational Site
-
Istanbul, Turkey, 34668
- GSK Investigational Site
-
Istanbul, Turkey, 34390
- GSK Investigational Site
-
Kayseri, Turkey, 38039
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the breast.
- Patients must be > 18 years of age
- Metastatic breast cancer (stage IV) at primary diagnosis or at relapse after curative intent therapy.
- Laboratory confirmed HER2/neu overexpressing and/or amplified disease in the invasive component of the primary or metastatic lesion
- Patients must have evidence of metastatic disease, but measurable disease is not mandatory.
- The patients may have received or not prior treatment with chemotherapeutic agents including taxanes, trastuzumab or anthracycline in the adjuvant or metastatic setting is permitted.
- Prior treatments with radiation therapy in the adjuvant and/or metastatic setting are permitted provided that at least 4 weeks have elapsed since the last fraction of radiation therapy and all treatment related adverse events are < grade 1 at the time of enrollment.
- Prior radiation to a solitary metastatic lesion is permitted provided that progression post radiation has been documented.
- Patients must have life expectancy > 3 months.
- ECOG performance status 0, 1 or 2 (see Appendix II).
- Patients must have normal organ and marrow function measured within 14 days prior to enrollment as defined Table 1.
- Left ventricular ejection fraction > 50% as demonstrated by MUGA scan/echocardiogram within 4 weeks prior to enrollment.
- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to enrollment and must use an acceptable method of contraception for the duration of the study.
Female patients who are lactating should discontinue nursing prior to the first dose of investigational product and should refrain from nursing throughout the treatment period and for 14 days following the last dose of investigational product.
- The patient must sign the consent form prior to enrollment.
- Patients must be accessible for treatment and follow-up.
Exclusion Criteria:
- Patients with a history of other malignancies, except: adequately treated DCIS, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours (non-breast) curatively treated with no evidence of disease for > 5 years.
- Patients receiving ongoing anticancer treatment or other investigational anti-cancer agents for breast cancer or patients who have used an investigational drug within 30 days or 5 half-lives (if known), whichever is longer, preceding the date of enrollment.
- Patients with symptomatic CNS metastases (including leptomeningeal involvement).
- Patients with only bone metastasis.
- Patients with serious cardiac illness or condition including, but not limited to:
history of documented congestive heart failure (CHF) or systolic dysfunction (LVEF<50%) high risk uncontrolled arrhythmias (ventricular tachycardia, high-grade AV-block, supraventricular arrhythmias which are not adequately rate-controlled) unstable angina pectoris requiring anti-anginal medication clinically significant valvular heart disease evidence of transmural infarction on ECG inadequately controlled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 100 mmHg).
New York Heart Association (NYHA) Class III or IV functional status (see Appendix X)
- Patients who have received vinorelbine as a prior therapy in the metastatic and recurrent setting.
- Patients with serious illness or medical condition which would not permit the patient to be managed according to the protocol including, but not limited to:
- History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
- Active uncontrolled infection. Serious or non-healing wound, ulcer, or bone fracture.
- Patients with GI tract disease resulting in an inability to take oral medication such as but not limited to malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption (for example resection of stomach or small bowel) or uncontrolled inflammatory GI disease (e.g. Crohn's, ulcerative colitis).
- Patients receiving CYP3A4 inhibitors or inducers are not eligible unless it has been > 7 and > 14 days, respectively since the last dose of medication before the start of protocol treatment (see Appendix IX). For amiodarone in particular, dosing is prohibited for at least 6 months prior to the start of protocol treatment.
- Patients with history of allergic or hypersensitivity reactions to any study drug or their excipients or with a history of allergic reactions attributed to compounds with similar chemical composition to any of the study drugs.
- Pregnant or lactation women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: lapatinib 1250mg
Patients will receive 1250mg lapatinib once a day for 24 weeks.
|
Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
|
Active Comparator: Vinorelbine 25mg/sqm
Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
|
Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants (Par.) With Clinical Benefit (CB) at Week 12 and Week 24
Time Frame: Week 12 and Week 24
|
Par. with CB are defined as those with complete response (CR), partial response (PR), or stable disease (SD) for >=12 or 24 weeks.
Per Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1, CR is defined as the disappearance of all target lesions, PR is defined as a >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD, and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as a reference the smallest sum LD since the treatment started.
|
Week 12 and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: From the start of treatment until disease progression, death, or discontinuation from the study (average of 102.7 months)
|
Per RECIST, Version 1.1, Progressive Disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
|
From the start of treatment until disease progression, death, or discontinuation from the study (average of 102.7 months)
|
Duration of Response
Time Frame: From the start of treatment until a complete response or partial response was reached (up to Week 90; average of 21.3 weeks)
|
Duration of response was measured in participants who experienced either a complete response or a partial response.
Per RECIST, Version 1.1, complete response is defined as the disappearance of all target lesions, and partial response is defined as a >=30% decrease in the sum of the longest diameter of target lesions, taking as a reference the baseline sum longest diameter.
|
From the start of treatment until a complete response or partial response was reached (up to Week 90; average of 21.3 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 112564
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on lapatinib and Vinorelbine
-
GlaxoSmithKlineTerminatedNeoplasms, BreastUnited States
-
Central European Cooperative Oncology GroupTerminatedMetastatic Breast CancerHungary, Austria
-
National Taiwan University HospitalGlaxoSmithKlineCompletedMetastatic Breast CancerTaiwan
-
Latin American Cooperative Oncology GroupGlaxoSmithKlineCompletedBRMS1 | Performance Status Zero to Two for Beginning the Study | Patient With a Maximum of One Chemotherapy | Patient With Progression After TaxanesArgentina, Brazil, Peru
-
Sun Yat-sen UniversityCompletedHER2 Positive Breast CancerChina
-
Sponsor GmbHGlaxoSmithKline; iOMEDICO AG; Arbeitsgemeinschaft fur Internistische Onkologie; Arbeitskreis Klinische StudienTerminatedMetastatic Breast Cancer | HER2 Positive | First or Second Line Therapy | Failure or Contraindication of Trastuzumab TherapyGermany
-
UNICANCERCompleted
-
University of California, DavisNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Byondis B.V.CompletedMetastatic Breast CancerFrance, United States, United Kingdom, Belgium, Spain, Italy, Singapore, Denmark, Sweden, Canada, Netherlands
-
Henan Cancer HospitalRecruiting